BIOMAT Database Logo BIOMAT Database Logo

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). 2002

G Wilcock, and H J Möbius, and A Stöffler, and
Bristol University, Department of Care of the Elderly, Frenchay Hospital, Bristol, UK.

The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). This was a 28-week, double-blind, parallel, randomized controlled trial of memantine 20 mg daily versus placebo which was conducted in 54 centres in the UK. Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist. Patients with a diagnosis of probable VaD and Mini Mental State Examination total scores between 10 and 22 were eligible for inclusion. Primary efficacy parameters were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and the Clinical Global Impression of Change (CGI-C). A total of 579 patients were randomized and 548 patients with at least one post-baseline efficacy assessment qualified for the intent-to-treat analysis. At endpoint, memantine was shown to improve cognition relative to placebo in VaD: the change of ADAS-cog from baseline differed by a mean of -1.75 points (95% confidence intervals -3.023 to -0.49) and a median of 2 points between the two groups, while CGI-C ratings showed no significant differences between treatment groups. A total of 77% of all memantine-treated patients experienced adverse event, versus 75% of the placebo-treated patients, dizziness being the most frequent adverse event (11% versus 8%, respectively). Memantine was well tolerated and safe.

UI MeSH Term Description Entries
D008297 Male Males
D008559 Memantine AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent. 1,3-Dimethyl-5-aminoadamantane,1-Amino-3,5-dimethyladamantane,Axura,D-145,D145,Ebixa,Memantin,Memantine Hydrochloride,Namenda,D 145
D008609 Mental Status Schedule Standardized clinical interview used to assess current psychopathology by scaling patient responses to the questions.
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D004244 Dizziness An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness. Lightheadedness,Orthostasis,Dizzyness,Light-Headedness,Light Headedness
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

G Wilcock, and H J Möbius, and A Stöffler, and
Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.
July 1992, Arzneimittel-Forschung,
G Wilcock, and H J Möbius, and A Stöffler, and
Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study.
April 1989, Journal of the American Geriatrics Society,
G Wilcock, and H J Möbius, and A Stöffler, and
Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia : Results of a Multicentre, Double-Blind, Placebo-Controlled Study.
June 1997, Clinical drug investigation,
G Wilcock, and H J Möbius, and A Stöffler, and
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
July 2009, The Lancet. Neurology,
G Wilcock, and H J Möbius, and A Stöffler, and
Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
February 2008, Journal of Alzheimer's disease : JAD,
G Wilcock, and H J Möbius, and A Stöffler, and
Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
July 2007, Journal of Alzheimer's disease : JAD,
G Wilcock, and H J Möbius, and A Stöffler, and
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.
October 2014, BMJ open,
G Wilcock, and H J Möbius, and A Stöffler, and
Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
February 2013, Journal of psychiatric research,
G Wilcock, and H J Möbius, and A Stöffler, and
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
July 2002, Stroke,
G Wilcock, and H J Möbius, and A Stöffler, and
Posatirelin in the treatment of vascular dementia: a double-blind multicentre study vs placebo.
June 1996, Acta neurologica Scandinavica,
Copied contents to your clipboard!